Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMXT 1501

Next Previous
Drug Profile

AMXT 1501

Alternative Names: AMX-513; AMX513 dicaprate; AMXT 1501 dicaprate; AMXT-1501

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aminex Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polyamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase 0 Glioma

Most Recent Events

  • 24 Dec 2024 Aminex Therapeutics terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, In children, In adolescents, In the elderly, In adults, Metastatic disease, Second-line therapy or greater) in USA and Australia (PO) because DFMO required reformulation from IV to capsule to maintain safety (NCT05500508)
  • 21 Aug 2024 Aminex Therapeutics suspended a phase-Ib/IIA trial in Solid tumours (Combination therapy, In adolescents, In children, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Australia and USA for evaluation of safety data (NCT05500508)
  • 18 Jun 2024 Milton S. Hershey Medical Center in collaboration with Aminex Therapeutics plans a phase I/II trial for Neuroblastoma, Glioma, and Sarcoma (In infants, In children, In adolescents, Combination therapy) in July 2024 (NCT06465199)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top